Nimbus Therapeutics' US challenge of Bristol Myers' acquisition of Celgene set for February 2022 trial
A challenge by Nimbus Therapeutics to Bristol Myers Squibb's $74 billion acquisition of Celgene was set for a February 2022 trial after the US judge overseeing the case rejected the parties’...To view the full article, register now.
Already a subscriber? Click here to view full article